Q4 2023 · 13F-HR
BVF INC/ILholdings as filed
Filed 2024-02-14 · accession 0000921895-24-000477
$4.00B
Reported value
70
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $1.31B | 32.9% | 21,751,284 | Common | SHARED |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $171.5M | 4.29% | 5,981,212 | Common | SHARED |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $157.7M | 3.95% | 1,981,100 | Common | SHARED |
| 74366E102 | PTGX | PROTAGONIST THERAPEUTICS INC | $131.7M | 3.30% | 5,744,848 | Common | SHARED |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $131.4M | 3.29% | 5,161,801 | Common | SHARED |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $129.0M | 3.23% | 4,370,024 | Common | SHARED |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $128.2M | 3.21% | 9,135,893 | Common | SHARED |
| 462222100 | IONS | IONIS PHARMACEUTICALS INC | $122.9M | 3.07% | 2,428,613 | Common | SHARED |
| 50127T109 | KURA | KURA ONCOLOGY INC | $106.0M | 2.65% | 7,373,228 | Common | SHARED |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $81.2M | 2.03% | 4,007,413 | Common | SHARED |
| 36315X101 | LKFT | GALAPAGOS NV | $77.8M | 1.95% | 1,915,109 | Common | SHARED |
| N5749R100 | 2GH | MERUS N V | $75.7M | 1.89% | 2,752,420 | Common | SHARED |
| 760273102 | RPTX | REPARE THERAPEUTICS INC | $75.4M | 1.89% | 10,333,600 | Common | SHARED |
| H00263105 | ACIU | AC IMMUNE SA | $72.9M | 1.82% | 14,571,236 | Common | SHARED |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $69.8M | 1.75% | 8,774,570 | Common | SHARED |
| 98419J206 | XOMA | XOMA CORP DEL | $67.2M | 1.68% | 3,633,743 | Common | SHARED |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $61.5M | 1.54% | 1,729,043 | Common | SHARED |
| 98985Y108 | ZYME | ZYMEWORKS INC | $61.0M | 1.53% | 5,870,000 | Common | SHARED |
| G3855L106 | GHRS | GH RESEARCH PLC | $60.3M | 1.51% | 10,400,158 | Common | SHARED |
| 29668H708 | EPIEUR | ESSA PHARMA INC | $57.7M | 1.45% | 8,748,629 | Common | SHARED |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $49.1M | 1.23% | 4,579,818 | Common | SHARED |
| 88427A107 | — | THIRD HARMONIC BIO INC | $47.9M | 1.20% | 4,365,933 | Common | SHARED |
| 282559103 | ETNBGBP | 89BIO INC | $45.2M | 1.13% | 4,047,354 | Common | SHARED |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $43.7M | 1.09% | 3,970,045 | Common | SHARED |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $41.0M | 1.03% | 890,072 | Common | SHARED |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $40.5M | 1.01% | 1,875,000 | Common | SHARED |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $37.9M | 0.95% | 2,739,595 | Common | SHARED |
| 528872302 | LXRX | LEXICON PHARMACEUTICALS INC | $37.4M | 0.94% | 24,435,632 | Common | SHARED |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $33.1M | 0.83% | 812,988 | Common | SHARED |
| 230031106 | CGEM | CULLINAN ONCOLOGY INC | $32.6M | 0.82% | 3,196,701 | Common | SHARED |
| 037326105 | ANTX | AN2 THERAPEUTICS INC | $32.0M | 0.80% | 1,563,963 | Common | SHARED |
| 03589W102 | ANNX | ANNEXON INC | $31.8M | 0.80% | 7,000,000 | Common | SHARED |
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $30.8M | 0.77% | 2,742,409 | Common | SHARED |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $26.2M | 0.66% | 1,508,416 | Common | SHARED |
| 01671P100 | ALLKGUSD | ALLAKOS INC | $23.3M | 0.58% | 8,552,417 | Common | SHARED |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $22.5M | 0.56% | 9,544,262 | Common | SHARED |
| 690469101 | OVID | OVID THERAPEUTICS INC | $22.1M | 0.55% | 6,851,051 | Common | SHARED |
| 29286M105 | — | ENGENE HOLDINGS INC | $20.8M | 0.52% | 2,251,037 | Common | SHARED |
| 13124Q106 | — | CALLIDITAS THERAPEUTICS AB | $19.3M | 0.48% | 750,000 | Common | SHARED |
| 89854M101 | TCRX | TSCAN THERAPEUTICS INC | $17.4M | 0.44% | 2,989,474 | Common | SHARED |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $17.0M | 0.43% | 1,521,948 | Common | SHARED |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $14.8M | 0.37% | 687,080 | Common | SHARED |
| 869367102 | — | SUTRO BIOPHARMA INC | $14.4M | 0.36% | 3,347,946 | Common | SHARED |
| 46565G104 | 5E7 | ITEOS THERAPEUTICS INC | $13.8M | 0.35% | 1,259,476 | Common | SHARED |
| 92337C203 | VSTM | VERASTEM INC | $13.7M | 0.34% | 1,685,219 | Common | SHARED |
| 45258J102 | IMVT | IMMUNOVANT INC | $12.6M | 0.32% | 300,000 | Common | SHARED |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $10.3M | 0.26% | 2,000,000 | Common | SHARED |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $10.2M | 0.26% | 6,595,801 | Common | SHARED |
| 45175G108 | — | IKENA ONCOLOGY INC | $9.4M | 0.24% | 4,769,164 | Common | SHARED |
| 92539P101 | — | VERVE THERAPEUTICS INC | $9.1M | 0.23% | 650,000 | Common | SHARED |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $7.8M | 0.19% | 4,326,710 | Common | SHARED |
| 78397T103 | SABS | SAB BIOTHERAPEUTICS INC | $6.3M | 0.16% | 9,178,282 | Common | SHARED |
| 92673K108 | VIGL | VIGIL NEUROSCIENCE INC | $6.1M | 0.15% | 1,813,633 | Common | SHARED |
| 171757107 | — | CIDARA THERAPEUTICS INC | $5.4M | 0.14% | 6,861,127 | Common | SHARED |
| 75082Q105 | — | RAIN ONCOLOGY INC | $4.2M | 0.11% | 3,526,729 | Common | SHARED |
| 24661P807 | DCTH | DELCATH SYS INC | $4.1M | 0.10% | 976,149 | Common | SHARED |
| 720795103 | PIRSEUR | PIERIS PHARMACEUTICALS INC | $3.8M | 0.09% | 20,609,863 | Common | SHARED |
| 50107A104 | KRON1USD | KRONOS BIO INC | $3.6M | 0.09% | 2,905,043 | Common | SHARED |
| H57830103 | — | NLS PHARMACEUTICS LTD | $3.4M | 0.08% | 5,747,126 | Common | SHARED |
| 46124U107 | IVA | INVENTIVA SA | $3.1M | 0.08% | 686,040 | Common | SHARED |
| 34962G109 | TOCAEUR | FORTE BIOSCIENCES INC | $2.5M | 0.06% | 2,982,105 | Common | SHARED |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $2.4M | 0.06% | 1,370,947 | Common | SHARED |
| 92765F108 | RYI | VIRACTA THERAPEUTICS INC | $2.1M | 0.05% | 3,614,662 | Common | SHARED |
| 608550208 | MTEMEUR | MOLECULAR TEMPLATES INC | $2.0M | 0.05% | 532,038 | Common | SHARED |
| 90466Y103 | — | UNICYCIVE THERAPEUTICS INC | $1.8M | 0.05% | 2,118,139 | Common | SHARED |
| 60853G106 | MOLN | MOLECULAR PARTNERS AG | $1.8M | 0.04% | 443,221 | Common | SHARED |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $1.2M | 0.03% | 2,312,200 | Common | SHARED |
| 29286M113 | — | ENGENE HOLDINGS INC | $803,592 | 0.02% | 945,402 | Common | SHARED |
| 04522R200 | — | ASLAN PHARMACEUTICALS LTD | $548,204 | 0.01% | 1,049,999 | Common | SHARED |
| 76200L309 | RZLT | REZOLUTE INC | $189,384 | 0.00% | 190,815 | Common | SHARED |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.